Trial Profile
Randomized phase II trial evaluating the efficacy and safety of standard care +/- continuous gefitinib treatment beyond progression in patients with advanced NSCLC after 1st line treatment with gefitinib (TORG1019)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2014
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Nov 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 19 Mar 2014 New trial record